The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors
Open accessAbstract
Background: Selected patients with advanced non-small cell lung cancer (NSCLC) benefit from immunotherapy, especially immune checkpoint inhibitors such as PD-1 (programmed cell death protein 1) inhibitor. Peripheral blood biomarkers would be most convenient to predict treatment outcome and immune-related adverse events (irAEs) in candidate patients. This study explored associations between inflammation-related peripheral blood markers and onset of irAEs and outcome in patients with advanced NSCLC receiving PD-1 inhibitors. Methods: A retrospective analysis was conducted of 102 patients with advanced NSCLC receiving PD-1 inhibitors from January 2017 to May 2019. Cox regression models were employed to assess the prognostic effect of low/high neutrophil/lymphocyte ratio (NLR), lactate dehydrogenase (LDH), and prognostic nutrition index (PNI) on overall survival (OS) and progression-free survival (PFS). Logistic regression models were used to analyze the correlation between peripheral blood markers and the onset of irAEs. Result: NLR < 5, LDH < 240 U/L, or PNI ≥ 45 was favorably associated with significantly better outcomes compared with higher, higher, or lower values, respectively. The multivariate analysis determined that these parameters were independently associated with both better PFS (p = 0.049, 0.046, 0.014, respectively) and longer OS (p = 0.007, 0.031, < 0.001, respectively). Patients with three favorable factors among NLR, LDH, and PNI had better PFS and OS than did those with two, one, or none. PNI and NLR were associated with the onset of irAEs. Conclusion: In patients with advanced NSCLC treated with PD-1 inhibitors, pretreatment NLR, LDH, and PNI may be useful predictive markers of clinical outcome and irAEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
[Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients].
Onodera, T., Goseki, N., & Kosaki, G. (1984) · PubMed · Cited by 1,688
Prognostic nutritional index in gastrointestinal surgery
Buzby, G. P., Mullen, J. L., Matthews, D. C., Hobbs, C. L., & Rosato, E. F. (1980) · The American Journal of Surgery · doi:10.1016/0002-9610(80)90246-9 · Cited by 1,552
Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,177
Diem, S., Schmid, S., Krapf, M., Flatz, L., Born, D., Jochum, W., Templeton, A. J., & Früh, M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.024 · Cited by 986
Mezquita, L., Auclin, E., Ferrara, R., Charrier, M., Remon, J., Planchard, D., Ponce, S., Ares, L. P., Leroy, L., Audigier-Valette, C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4771 · Cited by 913
Inflammation as a Tumor Promoter in Cancer Induction
Philip, M., Rowley, D. A., & Schreiber, H. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.006 · Cited by 640
Cancer immunotherapies targeting the PD-1 signaling pathway
Iwai, Y., Hamanishi, J., Chamoto, K., & Honjo, T. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0329-9 · Cited by 635
Bagley, S. J., Kothari, S., Aggarwal, C., Bauml, J. M., Alley, E. W., Evans, T. L., Kosteva, J. A., Ciunci, C. A., Gabriel, P. E., Thompson, J. C., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.01.013 · Cited by 511
Capone, M., Giannarelli, D., Mallardo, D., Madonna, G., Festino, L., Grimaldi, A. M., Vanella, V., Simeone, E., Paone, M., Palmieri, G., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0383-1 · Cited by 497
Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G. C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw016 · Cited by 395
Diem, S., Kasenda, B., Spain, L., Martin-Liberal, J., Marconcini, R., Gore, M., & Larkin, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.467 · Cited by 308
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R. R. H., Hospers, G. A. P., van den Eertwegh, A. J. M., Kapiteijn, E. W., de Groot, J. W. B., Soetekouw, P., Jansen, R. L., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1528-9 · Cited by 298
Tokunaga, R., Sakamoto, Y., Nakagawa, S., Miyamoto, Y., Yoshida, N., Oki, E., Watanabe, M., & Baba, H. (2015) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000458 · Cited by 268
Ferrucci, P. F., Gandini, S., Battaglia, A., Alfieri, S., Di Giacomo, A. M., Giannarelli, D., Cappellini, G. C. A., De Galitiis, F., Marchetti, P., Amato, G., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.180 · Cited by 262
Zaragoza, J., Caille, A., Bénéton, N., Bens, G., Christiann, F., Maillard, H., & Machet, L. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14155 · Cited by 156
Clinical Significance of Prognostic Nutritional Index After Surgical Treatment in Lung Cancer
Okada, S., Shimada, J., Kato, D., Tsunezuka, H., Teramukai, S., & Inoue, M. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2017.01.085 · Cited by 149
Soyano, A. E., Dholaria, B., Marin-Acevedo, J. A., Diehl, N. N., Hodge, D. O., Luo, Y., Manochakian, R., Chumsri, S., Adjei, A. A., Knutson, K. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0447-2 · Cited by 142
Nakaya, A., Kurata, T., Yoshioka, H., Takeyasu, Y., Niki, M., Kibata, K., Satsutani, N. M., Ogata, M., Miyara, T., & Nomura, S. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1250-2 · Cited by 132
Oya, Y., Yoshida, T., Kuroda, H., Mikubo, M., Kondo, C., Shimizu, J., Horio, Y., Sakao, Y., Hida, T., & Yatabe, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21602 · Cited by 113
Kiriu, T., Yamamoto, M., Nagano, T., Hazama, D., Sekiya, R., Katsurada, M., Tamura, D., TACHIHARA, M. Y., Kobayashi, K., & Nishimura, Y. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193018 · Cited by 99
Taniguchi, Y., Tamiya, A., Isa, S.-I., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.12030 · Cited by 66
Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Vecchio, M. D., Maio, M., Cappellini, G. C. A., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx059 · Cited by 51
Fujisawa, Y., Yoshino, K., Otsuka, A., Funakoshi, T., Fujimura, T., Yamamoto, Y., Hata, H., Tanaka, R., Yamaguchi, K., Nonomura, Y., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16427 · Cited by 50
The Prognostic Nutritional Index Predicts Survival and Identifies Aggressiveness of Gastric Cancer
Eo, W. K., Chang, H. J., Suh, J. H., Ahn, J. S., Shin, J., Hur, J.-Y., Kim, G. Y., Lee, S., Park, S., & Lee, S. (2015) · Nutrition and Cancer · doi:10.1080/01635581.2015.1082112 · Cited by 45
Watanabe, I., Kanauchi, N., & Watanabe, H. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy014 · Cited by 44
Kataoka, Y., Hirano, K., Narabayashi, T., Hara, S., Fujimoto, D., Tanaka, T., Ebi, N., Tomii, K., & Yoshioka, H. (2018) · Anticancer Research · doi:10.21873/anticanres.12259 · Cited by 32
Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles
Graves, M. C., Cellimarchett, G., van Zyl, B., Tang, D., Vilain, R. E., van der Westhuizen, A., & Bowden, N. A. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00113 · Cited by 24
Cited by
Targeting the gut microbiota for cancer therapy
Fernandes, M. R., Aggarwal, P., Costa, R. G. F., Cole, A. M., & Trinchieri, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00513-x · Cited by 290
Metadata
- Authors
- Peng, L., Wang, Y., Liu, F., Qiu, X., Zhang, X., Fang, C., Qian, X., & Li, Y.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2020-04-29
- Volume
- 69
- Issue
- 9
- Pages
- 1813-1822
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W3022919793
- Cited by
- 266
- References
- 34
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.